Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Sep;59(9):2036-9.
doi: 10.1007/s00125-016-4017-1. Epub 2016 Jun 15.

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

Paola Fioretto  1 , Bergur V Stefansson  2 , Eva Johnsson  2 , Valerie A Cain  3 , C David Sjöström  2
Affiliations
Randomized Controlled Trial

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

Paola Fioretto et al. Diabetologia. 2016 Sep.
No abstract available

Keywords: Albuminuria; Dapagliflozin; Renal impairment; SGLT2 inhibition; Type 2 diabetes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Adjusted mean changes (95% CI) in (a) UACR, (b) HbA1c, (c) body weight and (d) systolic BP, for dapagliflozin (DAPA) 10 mg, DAPA 5 mg and PBO, over 104 weeks. Mean change from baseline data (95% CI) were derived using the longitudinal repeated measures mixed model with fixed terms for treatment, study week, strata (pre-enrolment anti-hyperglycaemic therapy) study week-by-treatment interaction, as well as the fixed covariates of baseline and baseline-by-week interaction. The model also included an indicator variable to indicate if rescue had occurred at each visit. (a) Adjusted mean change in UACR at Week 104 for DAPA 10 mg: −43.9 (−64.3, −12.0); DAPA 5 mg: −26.4 (−55.0, 20.5) and PBO: 31.0 (−19.0, 111.9). (b) Adjusted mean change in HbA1c at Week 104 for DAPA 10 mg: −0.8 (−1.2, −0.4); DAPA 5 mg: −0.5 (−0.9, −0.1) and PBO: −0.4 (−0.8, 0.0). (c) Adjusted mean change in body weight at Week 104 for DAPA 10 mg: −1.6 (−3.5, 0.4); DAPA 5 mg: −1.0 (−2.9, 0.8) and PBO: 2.8 (0.8, 4.8). (d) Adjusted mean change in systolic BP at Week 104 for DAPA 10 mg: −7.6 (−13.3, −1.9); DAPA 5 mg: 0.1 (−6.6, 6.3) and PBO: 0.6 (−5.6, 6.9). Blue triangles, dapagliflozin 10 mg; red squares, dapagliflozin 5 mg; grey circles, placebo. BL, baseline; DAPA, dapagliflozin; PBO, placebo; SBP, systolic blood pressure
See this image and copyright information in PMC

References

    1. De Nicola L, Gabbai FB, Liberti ME, Sagliocca A, Conte G, Minutolo R. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis. 2014;64:16–24. doi: 10.1053/j.ajkd.2014.02.010. - DOI - PubMed
    1. Komala MG, Panchapakesan U, Pollock C, Mather A. Sodium glucose cotransporter 2 and the diabetic kidney. Curr Opin Nephrol Hypertens. 2013;22:113–119. doi: 10.1097/MNH.0b013e32835a17ae. - DOI - PubMed
    1. Schmieder RE, Schutte R, Schumacher H, et al. Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. Diabetologia. 2014;57:2019–2029. doi: 10.1007/s00125-014-3330-9. - DOI - PubMed
    1. Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA, Sjostrom CD. Dapagliflozin reduces albuminuria in hypertensive diabetic patients using renin-angiotensin blockers. Diabetes Obes Metab. 2016;18:590–597. doi: 10.1111/dom.12654. - DOI - PMC - PubMed
    1. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–971. doi: 10.1038/ki.2013.356. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data